New data point to how Keytruda changed lung cancer treatment; A Houston biotech earns early backers in quest to turn 'cold' tumors 'hot'
Keytruda became standard-of-care in non-small cell lung cancer in part thanks to clinical trials that ultimately showed it could boost survival to over two years …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
